Numbers:
Opinion:
I think that 2021 already and 2022 will be less closed than 2020, the vaccination rate is growing and despite the new strains, it reduces the number of deaths and severe cases.
It means that people will go out and do different things, which sometimes will lead to Anika Terapeutics
Point of entry:
I think there is a level at 39.6 $ +-, now it is being tested for the second time and I think if the test goes well and the Q2 report is >= expectations, that's a good entry point at $ 41/42.
Afterword:
I'm new to investing and trying to figure it out through trial and error.
This idea will allow me to collect feedback and document my own reasoning to get better.
Thanks for reading :)
- Expanded business in 2020: employee count +79% in 2020 y/y
- Small debt to equity - 0.08
- Big stock of finished goods (33.35 M in 2020 vs 8.78 M in 2019) will help smooth out losses in 2020
- Big buying volume in 30 Mar'21, maybe major player income (just a guess)
- 1Q 2021 results well above expectations - +260%
Opinion:
I think that 2021 already and 2022 will be less closed than 2020, the vaccination rate is growing and despite the new strains, it reduces the number of deaths and severe cases.
It means that people will go out and do different things, which sometimes will lead to Anika Terapeutics
Point of entry:
I think there is a level at 39.6 $ +-, now it is being tested for the second time and I think if the test goes well and the Q2 report is >= expectations, that's a good entry point at $ 41/42.
Afterword:
I'm new to investing and trying to figure it out through trial and error.
This idea will allow me to collect feedback and document my own reasoning to get better.
Thanks for reading :)